Fineline Cube

Follow:
14467 Articles
Company

Eli Lilly Commits Additional $4.5 Billion to Indiana Manufacturing – Genetic Medicine Facility Launches as Total Investment Exceeds $21 Billion

HospitalPolicy / Regulatory

China Elevates Pediatric Healthcare Infrastructure – NHC Expands National Children’s Medical Center Network to 14 Facilities

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline
Others

Kexing Pharmaceutical Launches HKEX Secondary Offering – Innovative Biopharma Seeks Capital to Advance Multimodal Pipeline

CompanyDrug

Sino Biopharmaceutical’s Subsidiary Tianqing Secures Expanded NMPA Approval for Saitanxin – First-in-Class CDK2/4/6 Inhibitor Moves to First-Line Breast Cancer

Others

Sino Biopharmaceutical Initiates Phase III Trial for LM-108 – CCR8-Targeted Antibody in Gastric Cancer Following Breakthrough Therapy Designations

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year
Company

BeOne Medicines Reports Record Q1 2026 Results – Brukinsa Crosses $1 Billion as Total Revenue Surges 35% Year-Over-Year

CompanyDrug

Cutia Therapeutics Secures NMPA Approval for CU-30101 Topical Anesthetic Cream – Dermatology Specialist Expands Commercial Portfolio

CompanyDrug

Changchun High-Tech’s Subsidiary GeneScience Advances GenSci155 – Long-Acting IGF-1 Analog for Preterm Infants and Stroke Patients

CompanyDeals

Amoytop Biotech Launches RMB 1.53 Billion Convertible Bond Offering to Fuel R&D and Manufacturing Expansion

CompanyDrug

Joincare Pharma Secures NMPA Clinical Trial Approval for JKN2501 – China’s First Broad-Spectrum β-Lactamase Inhibitor for Drug-Resistant Pneumonia

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China
CompanyDrug

Amgen Secures NMPA Approval for Evenity (Romosozumab) – Novel Osteoporosis Treatment for High-Risk Postmenopausal Women in China

CompanyDrug

NMPA Approves Hangzhou Biosunpharma’s Bewintinib as First-Line JAK2 Inhibitor for Myelofibrosis with 62.8% Spleen Volume Response Rate